From the Department of Physiology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois 60153
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
A perforated-patch whole-cell recording method was used to determine whether nitric oxide signaling participates in acetylcholine (ACh)-induced regulation of basal L-type Ca2+ current (ICa,L) in cat atrial myocytes. Exposure to 1 µM ACh for 2 min inhibited basal ICa,L (21 ± 3%), and withdrawal of ACh elicited rebound
stimulation of ICa,L above control (80 ± 13%) (n = 23). Stimulation of ICa,L elicited by withdrawal of ACh (but not
ACh-induced inhibition of ICa,L) was blocked by either 50 µM hemoglobin; 30 µM ODQ or 10 µM methylene blue,
inhibitors of soluble guanylate cyclase; 10 µM W-7, a calmodulin inhibitor; or 10 µM L-NIO, an inhibitor of constitutive NO synthase (NOS). In cells incubated in 5 mM l-arginine, ACh-induced rebound stimulation of ICa,L was
enhanced compared with control responses. Histochemical assay (NADPH diaphorase) indicated that atrial myocytes express constitutive NOS. NO-donor, spermine/NO (SP/NO), >1 µM stimulated basal ICa,L. SP/NO-induced
stimulation of ICa,L was inhibited by 50 µM hemoglobin, 30 µM ODQ, or 5 µM H-89, an inhibitor of PKA, and was
unchanged by 50 µM MnTBAP, a peroxynitrite scavenger. When ICa,L was prestimulated by 10 µM milrinone, an
inhibitor of cGMP-inhibited phosphodiesterase (type III) activity, SP/NO failed to further increase ICa,L. In cells
incubated in pertussis toxin (3.4 µg/ml for 6 h; 36°C), ACh failed to affect ICa,L, but 100 µM SP/NO or 10 µM milrinone still increased basal ICa,L. These results indicate that in cat atrial myocytes NO signaling mediates stimulation of ICa,L elicited by withdrawal of ACh but not ACh-induced inhibition of basal ICa,L. NO activates cGMP-induced
inhibition of phosphodiesterase (type III) activity. Upon withdrawal of ACh, this mechanism allows cAMP to recover to levels above control, thereby stimulating ICa,L. Pertussis toxin-sensitive G-proteins couple M2 muscarinic
receptors to NO signaling. NO-mediated stimulation of ICa,L elicited by withdrawal of ACh may be an important
mechanism that rapidly restores cardiac pacemaker and contractile functions after cholinergic suppression of
atrial activity.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Nitric oxide is an important second messenger that mediates a variety of cardiovascular functions (Kelly et al.,
1996), including cholinergic regulation of cardiac ICa,L
(Han et al., 1994
, 1995
, 1996
; Balligand et al., 1995
;
Habuchi et al., 1996
). For example, in the sinoatrial
node (Han et al., 1995
) or atrioventricular node (Han
et al., 1996
) cells, acetylcholine (ACh)1 inhibits prestimulated ICa,L via NO signaling mechanisms that activate cGMP-induced stimulation of phosphodiesterase
(PDE) activity. This mechanism is thought to contribute to accentuated antagonism, where cholinergic inhibition of cardiac function is enhanced by earlier
-adrenergic stimulation.
Previous work has shown that in cat atrial myocytes
exposure to ACh inhibits basal ICa,L and withdrawal of
ACh elicits a prominent rebound stimulation of ICa,L
above control (Wang and Lipsius, 1995). Rebound
stimulation of ICa,L elicited by ACh withdrawal is responsible for stimulation of atrial contractile (Wang
and Lipsius, 1995
) and pacemaker activities (Wang and
Lipsius, 1996
) above control, and can lead to the development of dysrhythmic atrial activity (Wang et al.,
1997
). A primary mechanism mediating the stimulatory
effects of ACh withdrawal is a rebound increase in
cAMP resulting from ACh-induced inhibition of PDE
(type III) activity (Wang and Lipsius, 1995
). Although
NO-cGMP signaling is known to modulate PDE activity
(Fischmeister and Mery, 1996
), it is not known to what
extent, if any, NO signaling contributes to ACh-induced
regulation of basal ICa,L in atrial myocytes. The purpose,
therefore, of the present study was to determine
whether NO signaling participates in ACh-induced regulation of ICa,L, especially in relation to stimulation of
ICa,L elicited by withdrawal of ACh.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cell Isolation
Details of the isolation and recording methods have been published previously (Wang and Lipsius, 1995). Atrial myocytes were isolated from cat heart. Adult cats of either sex were anesthetized with sodium pentobarbital (70 mg/kg i.p.). Hearts were perfused via a Langendorff apparatus with a bicarbonate-buffered Tyrode solution for ~5 min, followed by perfusion with a nominally
Ca2+-free Tyrode solution. After 5 min, the perfusion was
switched to a low (36 µM) Ca2+ Tyrode solution containing
0.06% collagenase (type II; Worthington Biochemical Corp.,
Freehold, NJ) for 30-40 min. After collagenase perfusion, both
atria were cut into small pieces and agitated in fresh collagenase
and 0.01% protease. Experiments were performed on either
right or left atrial cells, with no discernible differences. Cells
studied were isolated on the morning of the experiment.
Electrophysiological Recording Methods
Cells used for study were transferred to a small tissue bath on the
stage of an inverted microscope (Nikon Diaphot; Nikon Inc.,
Melville, NY) and superfused with a modified Tyrode solution containing (mM): 137 NaCl, 5.4 KCl, 1.0 MgCl2, 2.5 CaCl2, 5 HEPES, and 11 glucose, titrated with NaOH to a pH of 7.4. Solution was perfused through a small (0.3 ml) chamber by gravity at
~5 ml/min. The system required ~20 s to completely exchange
the bath contents. All experiments were performed at 35 ± 1°C.
Cells selected for study were elongated and quiescent. Ionic currents were recorded using a nystatin-perforated patch (Horn and
Marty, 1988) whole-cell recording method (Hamill et al., 1981
).
This method minimizes dialysis of intracellular contents with the
internal pipette solution, thereby maintaining physiological buffering of intracellular Ca2+ and second messenger signaling pathways (Zhou and Lipsius, 1993
). Nystatin was dissolved in DMSO
at a concentration of 50 mg/ml, and then added to the internal
pipette solution to yield a final nystatin concentration of 150 µg/
ml. The pipette solution containing nystatin is strongly sonicated
before use. The internal pipette solution contained (mM): 100 Cs-glutamate, 40 CsCl, 1.0 MgCl2, 4 Na2-ATP, 0.5 EGTA, 5 HEPES, titrated with CsOH to a pH of 7.2. To record ICa,L, ACh-activated K+ currents were blocked by Cs+ in the internal pipette
solution and 20 mM CsCl in the external solution. Addition of
CsCl to the external solution was not osmotically compensated. If
ACh elicited changes in background K+ conductance, the cell
was discarded.
A single suction pipette was used to record ionic currents (discontinuous voltage clamp mode) using an Axoclamp 2A amplifier (Axon Instruments, Inc., Foster City, CA). Once a gigaseal was formed, the access resistance was monitored until it stabilized, which generally required ~5 min. In the voltage clamp mode, the amplifier sampling rate was ~10-12 kHz. A second scope was used to monitor the duty cycle to ensure complete settling of the voltage transient between samples. Computer software (pCLAMP; Axon Instruments, Inc.) was used to deliver voltage protocols and acquire and analyze data. In addition, all signals were digitally recorded on VCR tape.
In general, ICa,L was activated by clamping cells from a holding
potential of 40 mV, to inactivate fast Na+ channels, to 0 mV for
200 ms every 5 s. Peak ICa,L was measured with respect to steady
state current and was not compensated for leak currents. Cells
were exposed to ACh for 2 min to elicit maximum rebound stimulation of ICa,L. Consecutive exposures to ACh were performed at
least 5 min apart to avoid any potential effects of desensitization.
Preliminary experiments indicate that this time interval allowed
reproducible effects of two consecutive ACh exposures on ICa,L.
Raw data were analyzed for statistical significance using paired
and unpaired Student's t tests and considered significant at P < 0.05. Data are expressed as mean ± SEM. In several experiments,
the effects of ACh on ICa,L were tested in the absence and then
presence of a drug or compound that alters NO signaling. The
percent change in ICa,L induced by ACh in the presence of a drug
or compound was determined in relation to the new baseline
ICa,L established by the drug or compound. The animal procedures used in this study were in accordance with the guidelines of
the Animal Care and Use Committee of Loyola University Medical Center.
Histochemical Methods
A histochemical assay (NADPH-diaphorase), as described previously (Prabhakar et al., 1993), was used to determine whether atrial myocytes express NOS activity. After cells were isolated, they were plated on microscope slides treated with laminin
(Sigma Chemical Co., St. Louis, MO). Then cells were fixed by
10% formalin and washed in PBS at pH 7.4. Fixed cells from the
same hearts were incubated for 1 h in PBS containing 0.3% Triton X-100, and 0.2 mM nitro blue tetrazolium, either in the absence (control) or presence of
-NADPH. In the presence of
-NADPH, NOS reduces tetrazolium to formazan, which appears
as a dark blue stain.
Drugs and Chemicals
Drugs and chemicals included acetylcholine chloride (Sigma
Chemical Co.), H-89 (N-[2-p-bromocinnamylamino]-5-isoquinolinesulfonamide) (Seikagaku America, Inc., Rockville, MD),
MnTBAP (Mn tetrakis [4-benzoic acid] porphyrin chloride) (Calbiochem Corp., La Jolla, CA), hemoglobin (Sigma Chemical Co.),
globin (Sigma Chemical Co.), W-7 (N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride) (Sigma Chemical Co.),
ODQ (1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one) (Sigma Chemical Co.), L-arginine and D-arginine (Sigma Chemical Co.); L-NIO
(L-N5-(1-iminoethyl)-ornithine (Alexis Corp., San Diego, CA)
and spermine/NO (Research Biochemicals, Inc., Natick, MA).
Stock solutions of H-89 and ODQ were prepared in DMSO. Final DMSO concentrations were 0.05% and had no effect on basal
ICa,L. Spermine/NO solutions were prepared fresh for each experiment and were not used for more than ~1 h.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
ACh-induced Inhibition and Rebound Stimulation of ICa,L
Fig. 1, A and B illustrates the effects of ACh exposure
and withdrawal on selected recordings of ICa,L (A) and
consecutive measurements of peak ICa,L (B) obtained
from a single atrial myocyte. Under control conditions,
exposure to 1 µM ACh for 2 min inhibited ICa,L by 36%.
Within 30 s of withdrawing ACh, ICa,L amplitude exhibited a prominent rebound stimulation of 141% above
control. ICa,L required ~4-5 min to return to a stable
baseline. Similar ACh-induced changes in ICa,L have
been reported previously (Wang and Lipsius, 1995). As
shown in Fig. 1 B, after the initial ACh exposure peak,
ICa,L generally stabilized at a level higher than the control baseline level. In other words, peak ICa,L did not always fully recover from the stimulatory effects of ACh
withdrawal even though the current reached a stable
level. This was more evident when the rebound stimulatory response was relatively large. This will be discussed
in more detail below. The main focus of this study was
to determine whether the ACh-induced changes in basal
ICa,L are mediated via NO signaling mechanisms.
|
Effects of Hemoglobin on ACh-induced Regulation of ICa,L
If ACh regulates ICa,L via production of NO then hemoglobin, a well known scavenger of NO, should inhibit
ACh-induced effects that are mediated by NO. Even
though hemoglobin is restricted to the external space,
because of its very high affinity for NO (Gibson and
Roughton, 1957), hemoglobin can inhibit intracellular NO signaling mechanisms by acting as a "sink" for intracellular NO (Beasley et al., 1991
; Balligand et al.,
1993
, 1995
). We therefore tested ACh in the presence
of hemoglobin. As shown in Fig. 1, A and B, once ICa,L
stabilized after the initial ACh exposure, exposure to
50 µM hemoglobin decreased ICa,L (
35%) to control baseline levels. In the presence of hemoglobin, ACh
decreased ICa,L by 40% and rebound stimulation of ICa,L
elicited by withdrawal of ACh was essentially abolished
(8%). In a total of five cells tested, in the absence and
presence of 50 µM hemoglobin, ACh decreased ICa,L by
21 ± 5% and 20 ± 6%, respectively, and ACh withdrawal stimulated ICa,L by 106 ± 21% and 13 ± 6%, respectively, a reduction of 88% (P < 0.02). Hemoglobin
alone decreased ICa,L amplitude (
22 ± 5%) to a value
that was not different from baseline control levels. In
four additional cells, lowering the hemoglobin concentration to 10 µM blocked stimulation of ICa,L elicited by
ACh withdrawal by 50%, without affecting ACh-induced
inhibition of ICa,L. Moreover, in three additional cells
we found that 10 µM globin had no effect on basal ICa,L
or ACh-induced rebound stimulation of ICa,L, suggesting that the effects of hemoglobin were due to the
binding of NO. These findings indicate that NO signaling is essential for rebound stimulation of ICa,L elicited
by ACh withdrawal but does not contribute to ACh-
induced inhibition of basal ICa,L.
ACh-induced NO Acts via cGMP Signaling
A common pathway for NO signaling is through activation of soluble guanylate cyclase and the production of
cGMP (Fischmeister and Mery, 1996). We therefore
tested the effects of ACh in the absence and presence
of ODQ, a potent and selective inhibitor of soluble guanylate cyclase activity (Brunner et al., 1996
; Garthwaite et al., 1995
). As shown in Fig. 2 A, under control conditions, 1 µM ACh elicited a typical inhibition of ICa,L
(
16%) and was followed, upon withdrawal of ACh, by
stimulation of ICa,L (60%) above control. Exposure to
30 µM ODQ alone slightly increased ICa,L (3%). In the
presence of ODQ, ACh inhibited ICa,L by 22% and rebound stimulation of ICa,L was abolished. In a total of four cells tested, in the absence and presence of ODQ,
ACh-induced inhibition of ICa,L was 16 ± 8% and 28 ± 8%, respectively, and stimulation of ICa,L elicited by
withdrawal of ACh was 95 ± 33% and 5 ± 6%, respectively (P < 0.02). ODQ alone increased ICa,L by 9 ± 4%.
Fig. 2 B shows the effects of 10 µM methylene blue, a
relatively nonselective and weak inhibitor of soluble
guanylate cyclase (Mayer et al., 1993
), on the responses
to ACh. Under control conditions, exposure to 1 µM
ACh inhibited ICa,L (
20%) and withdrawal of ACh
stimulated ICa,L (116%). Exposure to methylene blue
alone slightly increased ICa,L. In the presence of methylene blue, ACh induced inhibition of ICa,L (
34%) and
withdrawal of ACh failed to stimulate ICa,L. In the four
cells tested, in the absence and presence of methylene
blue, ACh-induced inhibition of ICa,L was 11 ± 3% and
30 ± 3%, respectively (P < 0.005), and withdrawal of
ACh changed ICa,L by 143 ± 37% and
7 ± 0.3%, respectively (P < 0.05). These findings provide further
support for the idea that ACh-induced NO acts via soluble guanylate cyclase and presumably cGMP signaling
to mediate rebound stimulation of ICa,L elicited by withdrawal of ACh. Moreover, they indicate that NO-cGMP
signaling does not mediate ACh-induced inhibition of
basal ICa,L.
|
NOS Mediates ACh-induced Rebound Stimulation of ICa,L
If ACh acts via NO signaling then inhibition of constitutive NOS should block ACh-induced changes in ICa,L
mediated by NO. In Fig. 3, A and B, we tested the effect
of L-NIO, an inhibitor of constitutive NOS (Rees et al.,
1990) on ACh-induced regulation of ICa,L. The left portion of Fig. 3 A shows control responses to ACh exposure and withdrawal; inhibition (
18%) followed by prominent rebound stimulation of ICa,L (74%). After
recovery from ACh, exposure to 10 µM L-NIO alone
decreased ICa,L by 20%. In the presence of L-NIO, reexposure to ACh still inhibited ICa,L (
16%) but rebound
stimulation of ICa,L was abolished. In the five cells
tested, in the absence and presence of L-NIO (Fig. 3
B), ACh inhibited ICa,L by 19 ± 5% and 23 ± 8%, respectively, and withdrawal of ACh stimulated ICa,L by
111 ± 38% and 1 ± 7%, respectively (P < 0.02). L-NIO
alone decreased ICa,L amplitude by 28 ± 5%. As noted
earlier, after withdrawal of the initial exposure to ACh,
ICa,L did not fully recover to its original control level.
Therefore, the effect of L-NIO alone simply decreased
ICa,L back to control baseline levels. These results suggest that ACh-induced activation of constitutive NOS
mediates rebound stimulation of ICa,L but not inhibition of ICa,L. If L-NIO blocked ACh-induced rebound
stimulation of ICa,L by specifically inhibiting NOS activity, then elevated levels of L-arginine, the substrate used
by NOS to synthesize NO (Mayer, 1995
), should restore
the effect of ACh. Therefore, in four additional cells we
tested ACh in the presence of 10 µM L-NIO in cells incubated (3 h) in 5 mM L-arginine. Under these conditions, ACh elicited a typical rebound stimulation of ICa,L
(65 ± 4%).
|
Calmodulin-dependent NOS Mediates ACh-induced NO Signaling
Activation of constitutive NOS activity is Ca-calmodulin
dependent (Bredt and Snyder, 1990). If ACh-induced
activation of NO signaling is mediated via constitutive
NOS, then rebound stimulation of ICa,L elicited by ACh
withdrawal should be blocked by inhibition of calmodulin. This idea was examined by testing the effects of ACh in the absence and then presence of W-7, a potent
inhibitor of calmodulin (Hidaka et al., 1981
; Asano,
1989
). As shown in Fig. 4, A and B, under control conditions (A), 1 µM ACh induced a typical inhibition
(
20%), and was followed, upon withdrawal of ACh, by
a prominent stimulation of ICa,L (89%). After recovery from ACh, the cell was exposed to 10 µM W-7 (Fig. 4
B), which decreased ICa,L (
8%) to the control level. In
the presence of W-7, ACh inhibited ICa,L (
17%) and
stimulation of ICa,L typically elicited by withdrawal of
ACh was essentially abolished. In the four cells tested,
in the absence and presence of 10 µM W-7, ACh inhibited ICa,L by 16 ± 3% and 16 ± 4%, respectively, and
withdrawal of ACh stimulated ICa,L by 60 ± 18% and
6 ± 8%, respectively (P < 0.02). W-7 alone decreased
ICa,L by 10 ± 2%, bringing ICa,L amplitude to the control
baseline level. These findings further support the conclusion that a constitutive Ca-calmodulin-dependent NOS mediates ACh-induced rebound stimulation of
ICa,L and does not mediate ACh-induced inhibition of
ICa,L.
|
Effect of L-arginine on ACh-induced NO Signaling
As noted earlier, L-arginine is the substrate used by
NOS to synthesize NO (Mayer, 1995). If NO signaling
participates in ACh-induced regulation of ICa,L, then exposure to a relatively high concentration of L-arginine
should accentuate the stimulatory response elicited by
ACh withdrawal. In one approach, we tested 1 µM ACh
in the absence and presence of 5 mM L-arginine in the same cell. The cell was acutely exposed to L-arginine
for 8 min between the first and second exposures to
ACh. In the absence of L-arginine, ACh decreased ICa,L
by 21 ± 5% and withdrawal of ACh stimulated ICa,L by
49 ± 6% (not shown). Exposure to L-arginine elicited a
small decrease in ICa,L (
13 ± 6%). After 8 min in L-arginine, a second exposure to ACh inhibited ICa,L by
23 ± 4% and withdrawal of ACh stimulated ICa,L by
73 ± 13% (n = 8). Although the stimulation of ICa,L
elicited by ACh withdrawal was enhanced, it did not
reach statistical significance (P = 0.09). It seemed possible that an 8-min exposure to L-arginine was not long
enough to significantly raise intracellular L-arginine
concentrations. Therefore, in a second approach, we
incubated atrial myocytes in 5 mM L-arginine for at
least 3 h before testing their response to ACh. Cells incubated in L-arginine for 3 h and those cells exposed to
L-arginine for 8 min were obtained from the same two hearts. Cells incubated in L-arginine (3 h) exhibited
basal ICa,L amplitudes not significantly different from
control cells. Fig. 5, A and B shows original ICa,L traces
from a typical experiment. In a cell not incubated in
L-arginine (Fig. 5 A), exposure to ACh induced inhibition and withdrawal of ACh induced stimulation of ICa,L
(49%). In another cell incubated in L-arginine (Fig. 5
B), ACh-induced inhibition of ICa,L was similar to control, but stimulation of ICa,L elicited by withdrawal of
ACh was enhanced (98%). In a total of six cells incubated in L-arginine, exposure to ACh decreased ICa,L by
11 ± 5% and withdrawal of ACh stimulated ICa,L by
109 ± 18%. Although ACh-induced inhibition of ICa,L
was smaller in cells incubated in L-arginine (
11 ± 5%) compared with control cells (
21 ± 5%), the differences in these unpaired data did not reach statistical
significance. Stimulation of ICa,L elicited by withdrawal
of ACh, however, was significantly larger in L-arginine-treated cells (109 ± 18%) compared with control (49 ±
6%) (P < 0.05). To examine the stereo specificity of
arginine, an additional experiment was performed
where cells were incubated in 5 mM D-arginine. Cells incubated in D-arginine showed a 25% smaller rebound
stimulation of ICa,L induced by ACh withdrawal than
control cells from the same heart (n = 2). The results
are consistent with the view that additional substrate
(L-arginine) for NO signaling augmented the stimulation of ICa,L elicited by withdrawal of ACh. In our previous study, we noted that the increase in ICa,L amplitude
elicited by ACh withdrawal ranged between 5 and
232% (SD ± 49%; n = 53) in any given cell (Wang and
Lipsius, 1995
). Based on the present results, this variability in response could be due to the dependence of
the rebound response on L-arginine concentration,
which may vary in individual myocytes after isolation.
|
Histochemical Assay for NOS Activity
So far, the results indicate that NO signaling underlies
the stimulation of ICa,L elicited by withdrawal of ACh. In
the next several experiments, we sought to determine
whether atrial myocytes exhibit constitutive NOS activity, and whether exogenous NO stimulates ICa,L in a way
similar to that elicited by withdrawal of ACh. In Fig. 6,
A and B, we used a histochemical technique (NADPH-diaphorase assay; Prabhakar et al., 1993) to demonstrate the presence of NO synthase activity. Isolated
atrial cells were fixed, permeabilized, and then incubated in nitro blue tetrazolium in the absence or presence of
-NADPH. Cells prepared in the absence of
-NADPH (Fig. 6 A) failed to exhibit a positive staining
reaction and those treated in the presence of
-NADPH
stained positively (Fig. 6 B). Similar results were obtained in cells isolated from three hearts.
|
Effect of NO Donors on ICa,L
Spermine NO (SP/NO) spontaneously releases NO
without the production of other biologically active by-products or intermediates (Maragos et al., 1991) and
therefore was used in the present study as our typical
NO donor. Fig. 7, A and B shows the effect of 100 µM
SP/NO on original ICa,L recordings (A) and the current-voltage relationship of ICa,L (B). As shown in Fig. 7
A, SP/NO elicited a reversible increase in basal ICa,L
amplitude (127%). SP/NO increased ICa,L throughout
the voltage range and shifted peak ICa,L ~5 mV more
negative without affecting the reversal potential. Because SP/NO spontaneously releases NO and therefore
decomposes to some extent over time (Maragos et al.,
1991
), we thought the construction of a dose-response
relationship would be quantitatively equivocal. However, to obtain a qualitative understanding of the effects of SP/NO, we tested different concentrations of
SP/NO (0.3, 1, 30, 100, and 300 µM) on basal ICa,L amplitude. These experiments indicated that concentrations of SP/NO
1 µM have no significant effect on
ICa,L and concentrations of SP/NO > 1 µM each elicited consistent dose-dependent increases in ICa,L. Concentrations of SP/NO
100 µM were essentially maximal. To ensure that the carrier compound, spermine,
was not responsible for the observed effects of SP/NO,
we tested 300 µM spermine alone and found no effect on ICa,L (n = 3) (not shown). These results indicate that
NO stimulates basal ICa,L. Moreover, they support the
results presented above that NO signaling mediates
stimulation of ICa,L elicited by withdrawal of ACh.
|
Effects of Hemoglobin and MnTBAP
The experiments shown in Fig. 8, A and B were performed to establish that the stimulatory effect of SP/ NO on basal ICa,L is due to NO. As shown in Fig. 8 A, 50 µM SP/NO elicited an increase in ICa,L that was maintained during exposure to SP/NO. Addition of 50 µM hemoglobin to the external solution inhibited the effects of SP/NO and returned ICa,L to control levels. When hemoglobin was removed in the continued presence of SP/NO, ICa,L increased once again (not shown), indicating that the effects of hemoglobin were reversible. In a total of four cells tested, SP/NO alone increased ICa,L by 61 ± 11% and hemoglobin returned ICa,L to levels not different from control (P < 0.001). The fact that hemoglobin blocked the stimulation of ICa,L elicited by both exogenous NO and ACh withdrawal supports the idea that both effects are mediated by a common mechanism; i.e., NO signaling.
|
NO can react with oxygen free radicals to produce
peroxynitrite, a biological active compound (Stamler et
al., 1992b). Although SP/NO does not generate oxygen
free radicals (Maragos et al., 1991
), it is possible that
oxygen free radicals produced endogenously may react
with NO released by SP/NO to affect ICa,L. To examine this point, we tested SP/NO in the absence and presence of MnTBAP, a superoxide dismutase mimetic and
peroxynitrite scavenger (Day et al., 1995
; Szabo et al.,
1996
). As shown in Fig. 8 B, exposure to 50 µM SP/NO
elicited a sustained increase in ICa,L. Addition of 50 µM
MnTBAP to the external solution failed to prevent the effects of SP/NO. In the three cells tested, SP/NO
alone increased ICa,L by 54 ± 17% and the addition of
MnTBAP had no significant effect on ICa,L amplitude
(56 ± 17%). In four additional cells, MnTBAP alone
exerted no significant effect on basal ICa,L amplitude. These findings, in conjunction with those presented in
Fig. 8 A, suggest that SP/NO is acting via NO, and not
peroxynitrite, to stimulate basal ICa,L. These results,
however, do rule out the possibility that NO may form
biologically active intermediates, such as S-nitrosothiols
(Ignarro et al., 1981
; Stamler et al., 1992a
; Arnelle and
Stamler, 1995
), that may stimulate ICa,L, as reported in
ferret ventricular myocytes (Campbell et al., 1996
). In ferret myocytes, however, the stimulatory effects of S-nitrosothiols were mediated by direct S-nitrosylation and/or
disulfide reactions and not via second messenger signaling mechanisms. The experiments presented below
will establish that in cat atrial myocytes NO is acting via
second messenger (cGMP) signaling.
NO Stimulates ICa,L via Soluble Guanylate Cyclase
The next question we addressed was whether exogenous NO acts via soluble guanylate cyclase and the production of cGMP. We therefore tested the effect of ODQ on SP/NO-induced stimulation of ICa,L. The original records in Fig. 9 show the effects of 300 µM SP/ NO on ICa,L in the absence (control) and presence of 30 µM ODQ. Under control conditions, SP/NO elicited a marked increase in ICa,L (129%) that reversed on washout. In the presence of ODQ, the stimulatory effects of SP/NO on ICa,L were abolished. In a total of three cells tested, SP/NO increased ICa,L by 130 ± 33% in the absence and by 15 ± 6% in the presence of ODQ (P < 0.05). ODQ alone had little effect on ICa,L amplitude. These experiments indicate that NO is acting via soluble guanylate cyclase and presumably cGMP to stimulate basal ICa,L. Moreover, they are consistent with the results presented above that NO acts via second messenger (cGMP) signaling to mediate stimulation of ICa,L elicited by withdrawal of ACh.
|
NO Acts via Inhibition of PDE and Stimulation of cAMP/PKA
Our previous study showed that milrinone, an inhibitor
of PDE (type III) activity (Harrison et al., 1986) attenuates rebound stimulation of ICa,L elicited by ACh withdrawal (Wang and Lipsius, 1995
). If SP/NO also is acting to stimulate ICa,L via inhibition of PDE (type III),
then earlier stimulation of ICa,L by milrinone should
prevent SP/NO from exerting any additional stimulation of ICa,L. As shown in Fig. 10, 100 µM SP/NO stimulated ICa,L (118%). Washout of SP/NO returned ICa,L toward control. Exposure to 10 µM milrinone stimulated
ICa,L to about the same extent as SP/NO (122%). This
finding indicates that cat atrial myocytes express PDE
(type III) activity, as reported previously (Wang and
Lipsius, 1995
). In the presence of milrinone, reexposure to SP/NO failed to further increase ICa,L, and, in
fact, elicited a small inhibition of ICa,L (
17%). In all
cells tested, SP/NO alone increased ICa,L by 117 ± 6%
(n = 3), milrinone alone increased ICa,L by 113 ± 33%
(n = 5), and the addition of SP/NO in the presence of
milrinone failed to further stimulate ICa,L (
17 ± 2%)
(n = 5). Interpretation of these experiments is based
on the premise that milrinone does not maximally stimulate ICa,L. In this regard, we have previously reported
in atrial myocytes that when ICa,L is prestimulated by 10 µM milrinone, 1 µM isoproterenol elicits an additional
increase in ICa,L of 101 ± 26% (n = 5) (Wang and Lipsius, 1995
), indicating that ICa,L is not maximally stimulated by milrinone. These results, in conjunction with
those described earlier, suggest that NO-cGMP signaling acts to inhibit PDE (type III) activity and thereby stimulate basal ICa,L via elevation of cAMP.
|
We previously reported that inhibition of cAMP-dependent PKA activity abolishes rebound stimulation of ICa,L
elicited by ACh withdrawal (Wang and Lipsius, 1995).
To determine whether exogenous NO stimulates ICa,L
via cAMP, SP/NO was tested in the absence and presence of H-89, an inhibitor of cAMP-dependent PKA activity (Chijiwa et al., 1990
). As shown in the bar graph
in Fig. 11, 100 µM SP/NO elicited a mean increase in
ICa,L of 108 ± 35%. In the presence of 5 µM H-89, the
stimulatory effect of SP/NO on ICa,L (36 ± 7%) was significantly reduced compared with control (P < 0.05;
n = 5). In three additional cells, the concentration of SP/NO was lowered (30 µM) to a level that elicited an
increase in ICa,L comparable to that achieved by ACh
withdrawal. In the absence and presence of H-89, 30 µM SP/NO elicited a mean increase in ICa,L of 61 ± 5%
and 14 ± 5%, respectively (P < 0.001). These findings
indicate that NO stimulates ICa,L primarily by increasing cAMP and are consistent with the role of NO signaling
in stimulation of ICa,L elicited by ACh withdrawal.
|
ACh-induced NO Signaling Is Pertussis Toxin-sensitive
Previous findings indicate that pertussis toxin (PTX)
blocks both ACh-induced inhibition and rebound stimulation of ICa,L (Wang and Lipsius, 1995). Based on the
present results, those findings indicate that PTX-sensitive G-proteins mediate ACh-induced NO signaling
mechanisms. To ensure that PTX does not interfere with steps in the NO signaling pathway downstream
from G-protein sites, we tested the effects of 1 µM ACh,
100 µM SP/NO, and 10 µM milrinone on atrial myocytes incubated in PTX (3.4 µg/ml for 6 h; 36°C). As
expected, in cells not incubated in PTX, ACh exposure and withdrawal elicited inhibition (
16 ± 9%) and
stimulation (124 ± 32%) of ICa,L, respectively (n = 4),
and SP/NO (208%; n = 2) and milrinone (137%; n = 2) also stimulated ICa,L. In cells preincubated in PTX
from the same hearts, the effects of ACh on ICa,L were
abolished (n = 5), whereas SP/NO and milrinone still increased ICa,L by 117 ± 35% and 99 ± 41%, respectively (n = 4). These results indicate that PTX does not
interfere with NO signaling sites downstream from
NOS, and suggests that PTX-sensitive G-proteins couple M2 muscarinic receptors to constitutive NOS.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In cat atrial myocytes, exposure to ACh inhibits basal
ICa,L and withdrawal of ACh elicits rebound stimulation
of ICa,L above control (Wang and Lipsius, 1995). Stimulation of ICa,L elicited by ACh withdrawal was shown to
involve ACh-induced inhibition of PDE (type III) activity. The present results extend our previous findings by
demonstrating that ACh-induced modulation of PDE is mediated via NO-cGMP signaling and that this is the
primary mechanism responsible for stimulation of ICa,L
elicited by ACh withdrawal. Thus, pharmacological interventions (hemoglobin, L-NIO, W-7, ODQ) that specifically block various steps in the NO-cGMP signaling pathway each blocked rebound stimulation of ICa,L,
whereas interventions expected to enhance NO signaling (incubation in L-arginine) enhanced stimulation of
ICa,L elicited by ACh withdrawal. In addition, activation
of NO signaling by exogenous NO (SP/NO) stimulated ICa,L, and its mechanism of action was essentially the
same as that underlying the stimulation of ICa,L elicited
by ACh withdrawal. In other words, SP/NO stimulated
ICa,L via cGMP-induced inhibition of PDE (type III) activity and elevation of cAMP. A similar mechanism has
been reported for NO-induced stimulation of basal ICa,L
in human atrial myocytes (Kirstein et al., 1995
). The
present study also provides histochemical evidence that
atrial myocytes express a constitutive form of NOS activity that can act as a substrate for the actions of ACh.
The same histochemical staining method has been
used to identify constitutive NOS in neuronal tissue (Hope et al., 1991
) and cardiac ventricular myocytes
(Zakharov et al., 1996
). More specific methods of immunohistochemistry, Northern blot analysis, or in situ
hybridization have revealed eNOS in human atrial tissue (Wei et al., 1996
), rat atrial (Seki et al., 1996
), and
rabbit AV nodal cells (Han et al., 1996
). It is interesting
to note that in guinea pig ventricular myocytes, withdrawal of ACh also elicits rebound stimulation of
cAMP-regulated chloride current (Zakharov and Harvey, 1997
). However, even though these cells express
constitutive NO synthase activity (Zakharov et al.,
1996
), ACh-induced rebound stimulation of chloride
current does not involve NO-cGMP signaling mechanisms (Zakharov and Harvey, 1997
).
The present findings also indicate that NO-cGMP signaling does not contribute to ACh-induced inhibition
of basal ICa,L. Thus, none of the drugs that blocked NO
signaling and rebound stimulation of ICa,L prevented
ACh-induced inhibition of ICa,L. This finding provides
further evidence that NO signaling plays a specific role in stimulation of basal ICa,L elicited by ACh withdrawal.
In our previous study, we reported preliminary experiments where L-NMMA, an inhibitor of NOS activity,
blocked ACh-induced inhibition of ICa,L, suggesting
that NO signaling may play a role in ACh-induced inhibition of basal ICa,L (Wang and Lipsius, 1995). Clearly,
that finding is not supported by the weight of evidence
obtained in the present study. To reexamine the role of
NOS in ACh-induced regulation of ICa,L, we found in
the present study that the NOS blocker L-NIO did not
prevent ACh-induced inhibition of ICa,L, although it
abolished stimulation of ICa,L elicited by ACh withdrawal. Moreover, the fact that elevated levels of L-arginine restored ACh-induced stimulation of ICa,L indicates that L-NIO acted specifically to inhibit NOS.
These results are consistent with all the other findings
in this study, which indicate that NO signaling does not
play a role in ACh-induced inhibition of basal ICa,L.
Others have reported that NO signaling plays a critical
role in the inhibitory effects of ACh on cardiac ICa,L
(Mery et al., 1991
, 1993
; Han et al., 1994
, 1995
, 1996
;
Levi et al., 1994
; Wahler and Dollinger, 1995
; Balligand
et al., 1995
). However, this inhibitory effect of NO signaling is obtained only when ICa,L is prestimulated by elevated cAMP. Under these conditions, NO-cGMP signaling is thought to inhibit ICa,L via stimulation of PDE
(Han et al., 1995
, 1996
) or activation of PKG activity
(Mery et al., 1991
; Levi et al., 1994
; Wahler and Dollinger, 1995
). Neither of these NO signaling mechanisms appear to play a role in ACh-induced inhibition
of basal ICa,L in cat atrial myocytes. We have found, however, that when ICa,L is prestimulated by isoproterenol,
SP/NO inhibits rather than stimulates ICa,L in cat atrial
myocytes (our unpublished observations). This finding
may explain the present observation that SP/NO inhibited ICa,L in cells prestimulated by milrinone (Fig. 10),
which acts by raising cAMP.
In the present experiments, ACh-induced inhibition
of basal ICa,L is evident (even enhanced) in the presence
of methylene blue in the external solutions. In rabbit SA
node pacemaker cells (Han et al., 1995), external application of methylene blue blocked ACh-induced inhibition
of prestimulated ICa,L as well as ACh-induced activation of
K+ current. However, when applied intracellularly, methylene blue only blocked ACh-induced inhibition of
ICa,L. From these findings, it was concluded that methylene blue blocks muscarinic receptors. A similar finding has been reported in rat ventricular myocytes (Abi
Gerges et al., 1997). The present results indicate that in cat atrial myocytes methylene blue does not block muscarinic receptors. It may be that methylene blue exerts
nonspecific receptor blocking effects that are species
dependent. Another interesting aspect of these experiments is that methylene blue very effectively blocked the
stimulation of ICa,L elicited by ACh withdrawal even
though it is considered a weak inhibitor of soluble guanylate cyclase activity. This may be explained by the fact that
methylene blue also is reported to inhibit NOS (Mayer et
al., 1993
), and therefore may act to block two critical sites
in the NO signaling pathway activated by ACh.
Each of the pharmacological compounds used in the present study to manipulate different steps in the NO signaling pathway exerted some direct effects on ICa,L. These effects could be interpreted to indicate that these cells produce endogenous levels of NO that could potentially modulate basal ICa,L. However, even though ICa,L stabilized after the initial ACh exposure peak, ICa,L generally did not fully recover to control levels, indicating some residual stimulatory effects of ACh. Therefore, ICa,L was not in a true basal state during the administration of each test compound. Those NO-blocking compounds that inhibited ICa,L returned ICa,L amplitude to control baseline values. Their actions, therefore, could be interpreted as blocking the residual NO-induced stimulatory effects exerted by the initial ACh exposure. However, other compounds that blocked NO signaling exerted small stimulatory effects on ICa,L. Their actions are less clear and may involve more complex effects on ICa,L. In any case, these experiments were not designed to examine the direct effects of these drugs on basal NO signaling mechanisms. Moreover, regardless of the direct drug effects, the results of these experiments are consistent with the conclusions that NO signaling mediates rebound stimulation of ICa,L elicited by ACh withdrawal.
Together with our previous work (Wang and Lipsius,
1995), the present results suggest that exposure to ACh
acts via M2 muscarinic receptors coupled to PTX-sensitive G-proteins to inhibit basal ICa,L, primarily via inhibition of the adenylate cyclase/cAMP/PKA cascade. At
the same time, ACh acts via PTX-sensitive G-proteins coupled to constitutive NOS to elicit NO-cGMP-induced
inhibition of PDE (type III) activity. Upon withdrawal
of ACh from the receptor, we speculate that adenylate
cyclase/cAMP activity recovers more rapidly than PDE
activity, resulting in an increase in cAMP above baseline
and rebound stimulation of ICa,L. These findings are supported by direct measurements of cAMP in chick heart
cells where withdrawal of cholinergic agonist acts via
PTX-sensitive G-proteins to elicit rebound stimulation
of adenylate cyclase activity and increases in cAMP concentrations above control levels (Linden, 1987
).
Functionally, ICa,L plays a critical role in the regulation of cardiac pacemaker and contractile activities. In
fact, rebound stimulation of ICa,L elicited by ACh withdrawal stimulates SA node pacemaker cell rate (Wang
and Lipsius, 1996) and atrial cell contraction (Wang
and Lipsius, 1995
) above control levels. Rebound stimulation of ICa,L elicited by ACh withdrawal also has been reported in catecholamine-treated Purkinje fibers (Ehara
and Mitsuiye, 1984
). This stimulatory effect of ACh on
ICa,L probably serves to rapidly restore cardiac pacemaker and contractile functions after periods of cholinergic suppression. Moreover, background
-adrenergic
stimulation augments rebound stimulation of cAMP (Linden, 1987
) and ICa,L (Wang and Lipsius, 1995
). This
suggests that in the presence of
-adrenergic stimulation NO signaling may mediate both enhanced ACh-induced inhibition of ICa,L (i.e., accentuated antagonism) and enhanced rebound stimulation of ICa,L. In
addition to stimulating Ca2+ influx via ICa,L, ACh-induced
stimulation of cAMP stimulates Ca2+ uptake into the
sarcoplasmic reticulum (Wang et al., 1997
). By loading
intracellular Ca2+ stores, withdrawal of ACh can Ca2+
overload the sarcoplasmic reticulum, thereby eliciting
Ca2+-mediated delayed afterdepolarizations and spontaneous/triggered atrial activities (Wang et al., 1997
).
This arrhythmogenic aspect of ACh withdrawal may be
enhanced by other preexisting conditions that raise intracellular Ca2+. This suggests that the NO signaling
mechanisms presented here may contribute to vagally
induced Ca2+-mediated atrial dysrhythmias. NO signaling, therefore, may be a potential target for antiarrhythmic drug therapies. The relevance of the present
results to human cardiac function is emphasized by the
fact that basal ICa,L in cat atrial myocytes and human atrial myocytes (Kirstein et al., 1995
) exhibit similar
stimulatory responses to NO signaling. Whether human
atrial myocytes exhibit similar responses to ACh remains to be determined.
![]() |
FOOTNOTES |
---|
Address correspondence to Stephen L. Lipsius, Ph.D., Department of Physiology, Loyola University Medical Center, 2160 S. First Avenue, Maywood, IL 60153. Fax: 708-216-6308; E-mail: slipsiu{at}wpo.it.luc.edu
Received for publication 30 April 1997 and accepted in revised form 21 October 1997.
We thank Dr. Jörg Hüser for helpful discussions regarding this work.
This work was supported by National Institutes of Health grant HL-27652 (to S.L. Lipsius).
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Abi Gerges, N., T. Eschenhagen, L. Hove-Madsen, P.-F. Mery, and R. Fischmeister. 1997. Methylene blue is a muscarinic antagonist in rat cardiac myocytes. Biophys. J. 72: A34 . (Abstr.) . |
2. |
Arnelle, D.R., and
J.S. Stamler.
1995.
NO+, NO., and NO![]() |
3. | Asano, M.. 1989. Divergent pharmacological effects of three calmodulin antagonists, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), chlorpromazine and calmidazolium, on isometric tension development and myosin light chain phosphorylation in intact bovine tracheal smooth muscle. J. Pharmacol. Exp. Ther. 251: 764-773 [Abstract]. |
4. | Balligand, J.-L., R.A. Kelly, P.A. Marsden, and T.W. Smith. 1993. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc. Natl. Acad. Sci. USA. 90: 347-351 [Abstract]. |
5. |
Balligand, J.-L.,
L. Kobzik,
X. Han,
D.M. Kaye,
L. Belhassen,
D.S. O'Hara,
R.A. Kelly,
T.W. Smith, and
T. Michel.
1995.
Nitric oxide-dependent parasympathetic signaling is due to activation of
constitutive endothelial (type III) nitric oxide synthase in cardiac
myocytes.
J. Biol. Chem.
270:
14582-14586
|
6. | Beasley, D., J.H. Schwartz, and B.M. Brenner. 1991. Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J. Clin. Invest. 87: 602-608 [Medline]. |
7. | Bredt, D.S., and S.H. Snyder. 1990. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. USA. 87: 682-685 [Abstract]. |
8. | Brunner, F., K. Schmidt, E.B. Nielsen, and B. Mayer. 1996. Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery. J. Pharmacol. Exp. Ther. 277: 48-53 [Abstract]. |
9. | Campbell, D.L., J.S. Stamler, and H.C. Strauss. 1996. Redox modulation of L-type calcium channels in ferret ventricular myocytes. J. Gen. Physiol. 108: 277-293 [Abstract]. |
10. |
Chijiwa, T.,
A. Mishima,
M. Hagiwara,
M. Sano,
K. Hayashi,
T. Inoue,
K. Naito,
T. Toshioka, and
H. Hidaka.
1990.
Inhibition of
forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-
dependent protein kinase, N-[2-(p- bromocinnamylamino)ethyl]-
5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
J. Biol. Chem.
265:
5267-5272
|
11. | Day, B.J., S. Shawen, S.I. Liochev, and J.D. Crapo. 1995. A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro. J. Pharmacol. Exp. Ther. 275: 1227-1232 [Abstract]. |
12. | Ehara, T., and T. Mitsuiye. 1984. Transient increase in the slow inward current following acetylcholine removal in catecholamine-treated guinea-pig Purkinje fibers. Jpn. J. Physiol. 34: 775-779 [Medline]. |
13. | Fischmeister, R., and P.-F. Mery. 1996. Regulation of Cardiac Ca 2 + channels by cGMP and NO. In Molecular Physiology and Pharmacology of Cardiac Ion Channels and Transporters. Morad M. Kluwer Academic Publishers, Boston, MA. 93-105. |
14. | Garthwaite, J., E. Southam, C.L. Boulton, E.B. Nielsen, and K. Schmidt. 1995. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol. Pharmacol. 48: 184-188 [Abstract]. |
15. | Gibson, Q.H., and F.J.W. Roughton. 1957. The kinetics and equilibria of the reactions of nitric oxide with sheep haemoglobin. J. Physiol. (Camb.). 136: 507-526 . |
16. |
Habuchi, Y.,
M. Nishio,
H. Tanaka,
T. Yamamoto,
L.-L. Lu, and
M. Yoshimura.
1996.
Regulation by acetylcholine of Ca2+ current in
rabbit atrioventricular node cells.
Am. J. Physiol.
271:
H2274-H2282
|
17. | Hamill, O.P., A. Marty, E. Neher, B. Sakmann, and F.J. Sigworth. 1981. Improved patch-clamp techniques for high resolution current recording from cells and cell-free membrane patches. Pflügers Arch. 391: 85-100 [Medline]. |
18. | Han, X., Y. Shimoni, and W.R. Giles. 1994. An obligatory role for nitric oxide in autonomic control of mammalian heart rate. J. Physiol. (Camb.). 476: 309-314 [Abstract]. |
19. | Han, X., Y. Shimoni, and W.R. Giles. 1995. A cellular mechanism for nitric oxide-mediated cholinergic control of mammalian heart rate. J. Gen. Physiol. 106: 45-65 [Abstract]. |
20. |
Han, X.,
L. Kobzik,
J.-L. Balligand,
R.A. Kelly, and
T.W. Smith.
1996.
Nitric oxide synthase (NOS3)-mediated cholinergic modulation of Ca2+ current in adult rabbit atrioventricular nodal cells.
Circ. Res.
78:
998-1008
|
21. | Harrison, S.A., D.H. Reifsnyder, B. Gallis, G.G. Cadd, and J.A. Beavo. 1986. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol. Pharmacol. 29: 506-514 [Abstract]. |
22. | Hidaka, H., Y. Sasaki, T. Tanaka, T. Endo, S. Ohno, Y. Fujii, and T. Nagata. 1981. N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation. Proc. Natl. Acad. Sci. USA. 78: 4354-4357 [Abstract]. |
23. | Hope, B.T., G.J. Michael, K.M. Knigge, and S.R. Vincent. 1991. Neuronal NADPH diaphorase is a nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 88: 2811-2814 [Abstract]. |
24. | Horn, R., and A. Marty. 1988. Muscarinic activation of ionic currents measured by a new whole-cell recording method. J. Gen. Physiol. 92: 145-159 [Abstract]. |
25. | Ignarro, L.J., H. Lippton, J.C. Edwards, W.H. Barricos, A.L. Hyman, P.J. Kadowitz, and C.A. Gruetter. 1981. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J. Pharmacol. Exp. Ther. 218: 739-749 [Medline]. |
26. |
Kelly, R.A.,
J.-L. Balligand, and
T.W. Smith.
1996.
Nitric oxide and
cardiac function.
Circ. Res.
79:
363-380
|
27. | Kirstein, M., M. Rivet-Bastide, S. Hatem, A. Benardeau, J.-J. Mercadier, and R. Fischmeister. 1995. Nitric oxide regulates the calcium current in isolated human atrial myocytes. J. Clin. Invest. 95: 794-802 [Medline]. |
28. | Levi, R.C., G. Alloatti, C. Penna, and M.P. Gallo. 1994. Guanylate-cyclase-mediated inhibition of cardiac ICa by carbachol and sodium nitroprusside. Pflügers Arch. 426: 419-426 [Medline]. |
29. |
Linden, J..
1987.
Enhanced cAMP accumulation after termination
of cholinergic action in the heart.
FASEB J.
1:
119-124
|
30. | Maragos, C.M., D. Morley, D.A. Wink, T.M. Dunams, J.E. Saavedra, A. Hoffman, A.A. Bove, L. Isaac, J.A. Hrabie, and L.K. Keefer. 1991. Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J. Med. Chem. 34: 3242-3247 [Medline]. |
31. | Mayer, B., F. Brunner, and K. Schmidt. 1993. Novel actions of methylene blue. Eur. Heart J. 14: 22-26 [Medline]. |
32. | Mayer, B. 1995. Biochemistry and molecular pharmacology of nitric oxide synthases. In Nitric Oxide in the Nervous System. S.R. Vincent, editor. Academic Press Inc., Orlando, FL. 22-42. |
33. | Mery, P.-F., S.M. Lohmann, U. Walter, and R. Fischmeister. 1991. Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc. Natl. Acad. Sci. USA. 88: 1197-1201 [Abstract]. |
34. |
Mery, P.-F.,
C. Pavoine,
L. Belhassen,
F. Pecker, and
R. Fischmeister.
1993.
Nitric oxide regulates cardiac Ca2+ current.
J. Biol.
Chem.
268:
26286-26295
|
35. | Prabhakar, N.R., G.K. Kumar, C.-H. Chang, F.H. Agani, and M.A. Haxhiu. 1993. Nitric oxide in the sensory function of the carotid body. Brain Res. 625: 16-22 [Medline]. |
36. | Rees, D.D., R.M.J. Palmer, R. Schulz, H.F. Hodson, and S. Moncada. 1990. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol 101: 746-752 [Abstract]. |
37. | Seki, T., H. Hagiwara, K. Naruse, M. Kadowaki, M. Kashiwagi, H. Demura, S. Hirose, and M. Naruse. 1996. In situ identification of messenger RNA of endothelial type nitric oxide synthase in rat cardiac myocytes. Biochem. Biophys. Res. Commun. 218: 601-605 [Medline]. |
38. | Stamler, J., D. Simon, J. Osborne, M. Mullins, O. Jaraki, T. Michel, D. Singel, and J. Loscalzo. 1992a. S-Nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc. Natl. Acad. Sci. USA. 89: 444-448 [Abstract]. |
39. | Stamler, J.S., D.J. Singel, and J. Loscalzo. 1992b. Biochemistry of nitric oxide and its redox-activated forms. Science. 258: 1898-1902 [Medline]. |
40. | Szabo, C., B.J. Day, and A.L. Salzman. 1996. Evaluation of the relative contribution of nitric oxide and peroxynitrite to the suppression of mitochondrial respiration in immunostimulated macrophages using a manganese mesoporphyrin superoxide dismutase mimetic and peroxynitrite scavenger. FEBS Lett. 381: 82-86 [Medline]. |
41. |
Wahler, G.M., and
S.J. Dollinger.
1995.
Nitric oxide donor SIN-1 inhibits mammalian cardiac calcium current through cGMP-dependent protein kinase.
Am. J. Physiol.
268:
C45-C54
|
42. |
Wang, Y.G.,
J. Hüser,
L.A. Blatter, and
S.L. Lipsius.
1997.
Withdrawal of acetylcholine elicits Ca2+-induced delayed afterdepolarization in cat atrial myocytes.
Circulation.
96:
1275-1281
|
43. |
Wang, Y.G., and
S.L. Lipsius.
1995.
Acetylcholine elicits a rebound
stimulation of Ca2+ current mediated by pertussis toxin-sensitive
G protein and cAMP-dependent protein kinase A in atrial myocytes.
Circ. Res.
76:
634-644
|
44. |
Wang, Y.G., and
S.L. Lipsius.
1996.
A cellular mechanism contributing to post-vagal tachycardia studied in isolated pacemaker cells
from cat right atrium.
Circ. Res.
79:
109-114
|
45. | Wei, C.-M., S.-W. Jiang, J.A. Lust, R.C. Daly, and C.G.A. McGregor. 1996. Genetic expression of endothelial nitric oxide synthase in human atrial myocardium. Mayo Clin. Proc. 71: 346-350 [Medline]. |
46. |
Zakharov, S.I., and
R.D. Harvey.
1997.
Rebound stimulation of the
cAMP-regulated Cl![]() |
47. |
Zakharov, S.I.,
S. Pieramici,
G.K. Kumar,
N.R. Prabhakar, and
R.D. Harvey.
1996.
Nitric oxide synthase activity in guinea pig ventricular myocytes is not involved in muscarinic inhibition of cAMP-regulated ion channels.
Circ. Res.
78:
925-935
|
48. | Zhou, Z., and S.L. Lipsius. 1993. Effect of isoprenaline on If current in latent pacemaker cells isolated from cat right atrium: ruptured vs perforated patch whole-cell recording methods. Pflügers Arch. 423: 442-447 [Medline]. |